Navigation Links
Global Biotech and Pharmaceutical Conference Early Bird Registration Discounts End This Week
Date:9/12/2012

FARMINGTON, Conn., Sept. 12, 2012 /PRNewswire-iReach/ -- Bio-IT World Expo Europe 2012 October 9-11, 2012 - Vienna, Austria

(Photo: http://photos.prnewswire.com/prnh/20120912/CG73074)

The Fourth Annual Bio-IT World Europe Conference & Expo attracts life sciences, pharmaceutical, informatics and IT professionals from across Europe and the rest of the world. This year's conference will feature four tracks: Clinical Genomics; Data Infrastructure and High Performance Computing; Drug Discovery Informatics to Personalized Therapeutics; and Cloud-Based Bioinformatics. A unique opportunity to share research advances, information trends and new enabling technologies that are driving biomedical research and drug development.

Keynote speakers are to include Yike Guo, Ph.D., Professor of Computing Science at Imperial College London; Ian Dix, Ph.D., Director of Analytics, Information and Knowledge Engineering (AIKE), and R&D Information at AstraZeneca; Paul Flicek, Ph.D., Principal Investigator & Head of Vertebrate Genomics Team, EMBL-European Bioinformatics Institute; Hermann Hauser, Entrepreneur and Partner at Amadeus Capital Partners; Eric D. Perakslis, Ph.D., CIO and Chief Scientist of Informatics at the U.S. Food and Drug Administration (FDA); Alison Davis, Director of Information Management at the Medicines and Healthcare Products Regulatory Agency (MHRA); and Luc Verhelst, CIO at  the European Medicines Agency (EMA).

Early bird discounts expire this week, register through GII to save nearly $200 before September 14 at http://www.giiconference.com/chi229590-2012/

PK/PD of Novel Constructs
October 10 - 12, 2012 - Bethesda, MD, USA

Understanding the activity of novel constructs in animal models and clinical studies is critical to their success. There are numerous constructs of bispecific and multiclonal antibodies, antibody-drug conjugates, and antibody fragments heading to the clinic that are diverse in nature. This conference will delve into tools for understanding effects in humans and engineering for optimal efficacy, safety and metabolism, and strive to uncover the link between immunogenicity and pK/pD.

Keynote speakers are to include Louis M. Weiner, M.D., Director, Lombardi Comprehensive Cancer Center; Professor and Chair, Department of Oncology, Georgetown University Medical Center; Joseph P. Balthasar, Ph.D., Professor, Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, SUNY Buffalo; and Vibha Jawa, Ph.D., Principal Scientist, Clinical Immunology, Amgen

Early bird discounts expire this week, register through GII to save $200 before September 14 at http://www.giiconference.com/chi240526-2012/

Immunogenicity Summit 2012
10-12 October 2012 - Bethesda, MD, USA

The Leading Summit Connecting Industry, Academia and Regulators on Immunogenicity Testing, Immunogenicity Avoidance and Regulatory Guidance

Following year-on-year success, CHI presents their fourth Immunogenicity Summit. We will continue to provide strong interaction and discussion with the regulatory authorities (40 FDA representatives in 2011), updates on immunogenicity testing strategies and means of controlling immunogenicity. New this year will be a focus on characterization and impact of immune complexes, in vivo assessment with immune tolerant mice, and anti-idiotype assays for hypersensitivity.  Last year's attendance was up by 20% with over 250 attendees representing over 50 global organizations.

Keynote & featured Speakers are to include: Steve J. Swanson, Ph.D., Director, Medical Sciences, Clinical Immunology, Amgen; Amy Rosenberg, M.D., Director, Therapeutic Proteins, CDER/FDA; Susan Kirshner, Ph.D., Associate Chief, Laboratory of Immunology, Therapeutic Proteins, Biotechnology, CDER/FDA; Daniela Verthelyi, M.D., Ph.D., Chief, Immunology, Therapeutics Proteins, CDER/FDA; Jack Ragheb, M.D., Ph.D., Principal Investigator, Immunology, Therapeutic Proteins, CDER/FDA; Paul Chamberlain, NDA Advisory Board; Roy Jefferis, Ph.D., C.Chem, FRSC, MRCP, FRCPath, D.S., Professor Emeritus, School of Immunity & Infection, University of Birmingham UK; and Valerie Quarmby, Ph.D., Director and Principal Scientist, BioAnalytical Sciences, Genentech, Inc.

Early bird discounts expire this week, register through GII to save nearly $200 before September 14 at http://www.giiconference.com/chi240525-2012/

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Novo Nordisk and BGI establish global collaboration framework
2. EU-funded study underlines importance of Congo Basin for global climate and biodiversity
3. Global warming threat to coral reefs: Can some species adapt?
4. 1 solution to global overfishing found
5. Young researcher taking fight against global killer to the next level in Vietnam
6. Heightened Security Threats and Economic Issues Provide Fillip to Global Civil and Military Biometrics Market, Says Frost & Sullivan
7. Global Information Inc. Announces Discounted Conference Registration For Bio-IT World Asia and Biodetection Technologies 2012
8. Global effort launched to save turtles from extinction
9. New Biotech and Pharmaceutical Market Research from Global Information Inc Forecasts Strong Growth Coming Out of Recession
10. 2012 Forecast for US Molecular Diagnostics Market Now Available From Global Information Inc.
11. Desert to Rainforest global classroom links future teachers, classrooms in Phoenix and Panama
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology: